Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ASP0739 |
Trade Name | |
Synonyms | aAVC ASP0739|aAVCs ASP0739|ASP 0739|ASP-0739 |
Drug Descriptions |
ASP0739 are human artificial adjuvant vector cells loaded with the CD1d ligand alpha-galactosylceramide and modified to express the tumor associated antigen NY-ESO-1 (CTAG1B), which potentially induce activation of immune cells, and cytotoxic T-cell mediated response against tumor cells expressing NY-ESO-1 (NCI Thesaurus). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C181663 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ASP0739 | ASP0739 | 0 | 1 |
ASP0739 + Pembrolizumab | ASP0739 Pembrolizumab | 0 | 1 |